Gland Pharma
Gland Pharma Limited, commonly referred to as Gland Pharma, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Established in 1978, the company has made significant strides in the development and manufacturing of high-quality injectable pharmaceuticals, particularly in the areas of oncology, anaesthesia, and critical care. With a strong presence in both domestic and international markets, Gland Pharma has earned a reputation for its robust product portfolio, which includes a range of generic injectables and complex formulations. The company is recognised for its commitment to quality and innovation, having achieved several key milestones, including successful partnerships with global healthcare providers. Gland Pharma's dedication to excellence positions it as a leader in the injectable segment, contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Gland Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gland Pharma's score of 21 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gland Pharma's reported carbon emissions
In 2023, Gland Pharma reported total carbon emissions of approximately 11929600 kg CO2e for Scope 1 and about 80669600 kg CO2e for Scope 2. This represents a slight decrease in Scope 1 emissions from 12579300 kg CO2e in 2022, while Scope 2 emissions increased from 78475200 kg CO2e in the previous year. For 2024, Gland Pharma's emissions are projected to rise, with Scope 1 emissions estimated at 15736000 kg CO2e and Scope 2 emissions at 81154000 kg CO2e. Despite these fluctuations, the company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. Gland Pharma's emissions intensity, measured as total Scope 1 and Scope 2 emissions per rupee of turnover, shows a trend of improvement, with a value of 0.05728 in 2023 and 0.05237 in 2024, indicating a commitment to reducing emissions relative to revenue. However, the absence of formal reduction targets suggests that further clarity on their long-term climate commitments is needed.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 12,579,300 | 00,000,000 | 00,000,000 |
| Scope 2 | 78,475,200 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gland Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
